GENFIT Reports €65.4M Revenue, €101.1M Cash as Iqirvo® Sales Surge
Event summary
- GENFIT reported €65.4M revenue for 2025, down slightly from €67.0M in 2024, driven by €21.8M in royalty revenue from Iqirvo® sales.
- Cash position stood at €101.1M as of December 31, 2025, with €17.0M milestone payment from Ipsen not yet reflected in cash.
- Iqirvo® achieved $208M in net sales in 2025, triggering a €17.0M milestone payment to GENFIT.
- ACLF and CCA programs progressing according to plan, with preliminary Phase 1 data for G1090N showing promising anti-inflammatory activity.
- Ipsen initiated a global Phase 3 clinical trial for Iqirvo® in Primary Sclerosing Cholangitis (PSC).
The big picture
GENFIT's financial update highlights the strategic importance of its partnership with Ipsen, particularly the commercial success of Iqirvo® in PBC. The company's focus on rare liver diseases positions it in a niche but growing segment of the biopharmaceutical market. The progress in ACLF and CCA programs underscores GENFIT's commitment to addressing unmet medical needs, potentially opening new revenue streams through future regulatory approvals and milestone payments.
What we're watching
- Revenue Growth
- Whether GENFIT can sustain revenue growth through milestone payments and royalty revenue from Iqirvo® sales.
- Clinical Progress
- The pace at which GENFIT advances its ACLF and CCA programs into Phase 2 trials.
- Regulatory Approvals
- How the regulatory approval process for Iqirvo® in PSC will impact GENFIT's future milestone payments and royalties.
Related topics